Mohammed Azman – CEO, PERKESO, Malaysia
Dato’ Sri Dr Mohammed Azman, CEO at PERKESO, the Malaysian Social Security Organization, explains PERKESO’s main areas of focus as well as the current health burdens the organization is looking…
Address: Peti #8, Wisma Selangor Dredging, 5th Floor, South Block, 142-A, Jalan Ampang, 50450 Kuala Lumpur, Malaysia
Tel: +603 2161 4181
Web: http://www.ranbaxy.com/operations/operationcountry.aspx?Cid=67&flag=&Rid=61
Ranbaxy Laboratories Limited (Ranbaxy), India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries.
In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing.
Ranbaxy’s mission is ‘To become a Research-based International Pharmaceutical Company’. The Company is driven by its vision to ‘Achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets’.
Recognized as a leading manufacturer, Ranbaxy Malaysia was set up as a wholly owned subsidiary in June 1984.
With its excellent sales and marketing team, who are experienced and well versed with the industry, the company today has strong brand recognition amongst the General Practitioners, Government Hospitals and Retail Pharmacy sector. The marketing and distribution of Ranbaxy’s products is also undertaken for Schwarz Pharma and Desitin, Germany and Pharmascience, Canada.
Using the finest R&D and Manufacturing facilities, Ranbaxy Laboratories Limited manufacture and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. The Company remains focused on ascending the value chain in the marketing of pharmaceutical substances and is determined to bring in increased revenues from dosage forms sales.
Ranbaxy’s diverse product basket of over 5,000 SKUs available in over 125 countries worldwide, encompasses a wide therapeutic mix covering a majority of the chronic and acute segments. Healthcare trends project that the chronic treatment segments will outpace the acute treatment segments, primarily driven by a growing aging population and dominance of lifestyle diseases. Our robust performance in Cardiovasculars, Central Nervous System, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology segments, clearly indicates that the Company has strengthened its presence in the fast-growing chronic and lifestyle disease segments.
Top 10 Products (2009)
• Valacyclovir
• Simvastatin
• Co-Amoxyclav
• Ciprofloxacin and Combinations
• Amoxycillin and Combinations
• Isotretinoin
• Ketorolac Tromethamine
• Loratadine and Combinations
• Ginseng+Vitamins
• Cephalexin
• Atorvastatin and Combinations
Dato’ Sri Dr Mohammed Azman, CEO at PERKESO, the Malaysian Social Security Organization, explains PERKESO’s main areas of focus as well as the current health burdens the organization is looking…
Jennifer Lopez, executive director of the British Malaysian Chamber of Commerce, discusses foreign investment trends in Malaysia and how the chamber is serving its members, especially UK companies operating in…
Lim Teng Chyuan, president of the Malaysian Association for Pharmaceutical Suppliers (MAPS), discusses the association’s role in solving and supporting its members with the numerous regulatory issues and compliance requirements…
Amrahi Buang, president of the Malaysian Pharmaceutical Society details the ‘lack’ of recognition and integration of pharmacists in Malaysia. He also explains the complex dual healthcare system and the governmental…
The managing director of Boston Consulting Group Malaysia discusses the gap between public and private healthcare in the country, and what can be done to bridge it. What appears…
Professor Kenneth K. C. Lee, Head of the School of Pharmacy at Monash University Malaysia, discusses the institution’s position as a hub for health economics in the Asia Pacific region…
Rhenu Bhuller provides insight into Malaysia’s healthcare industry positioning in the Southeast Asian region and the ability to provide affordable quality healthcare in a country that is naturally diverse as…
Klaus Boehncke and Yennie Tan from PwC Malaysia discuss the factors that will make the country a hub for medical tourism and the importance of listening to patient demands at…
Dr. Hassan, founder and CEO of Healwell and House of Healin, brings research and entrepreneurship together with the aim of turning Malaysian traditions into scientific innovation. Could you share…
Alan Ong, executive vice president for the Asia/Pacific region at INC Research, outlines the key challenges and opportunities that CROs face in the Malaysian clinical trial segment and describes INC’s…
Bayer Malaysia’s managing director, Thomas Steffen, discusses the key differences and opportunities offered by the Malaysian market and calls for more information to help the promotion of oral contraception in…
Sanofi’s general manager for Malaysia, Singpoare and Brunei discusses the benefits of implementing of a new channel business model and proudly showcases the dengue vaccine, 20 years after the company initiated…
See our Cookie Privacy Policy Here